QRxPharma faces third FDA knockback for Moxduo


By Dylan Bushell-Embling
Thursday, 24 April, 2014


QRxPharma faces third FDA knockback for Moxduo

Shares in QRxPharma (ASX:QRX) sank 80% on Wednesday after the company revealed that it’s facing another regulatory knockback in the US for its dual-opioid pain product MoxDuo.

The Anaesthetic and Analgesic Drug Products Advisory Committee has recommended against approval of the immediate-release version of Moxduo, a dual-opioid formulation of morphine and oxycodone, for the treatment of moderate to severe acute pain.

The committee found that QRxPharma failed to provide sufficient evidence to warrant approval of the product at this time.

The FDA has already issued two complete response letters in response to QRxPharma’s New Drug Applications (NDA) for the product. The company filed its third NDA in November.

“We are obviously disappointed in the outcome of [the] meeting, but remain confident in the advantages of Moxduo compared to morphine and oxycodone,” QRxPharma CEO Dr John Holaday said. These include a potentially reduced side-effect profile compared to taking just one opioid.

“We are committed to bringing to market safer therapies for pain, such as Moxduo, and preventing opioid abuse.”

QRxPharma (ASX:QRX) shares fell 80% to $0.14 on Wednesday, and were trading 14.29% lower at $0.12 as of around 1 pm on Thursday.

Related Articles

Aspirin could prevent some cancers from spreading

The research could lead to the targeted use of aspirin to prevent the spread of susceptible types...

Heat-induced heart disease is killing Australians

Hot weather is responsible for an average of almost 50,000 years of healthy life lost to...

Call for greater diversity in genomics research

A gene variant common in Oceanian communities has been misclassified as a potential cause of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd